COVID-19对肺功能、运动能力和生活质量的中期影响
研究纳入379例SARS-CoV-2确诊患者,在诊断后4个月评估肺功能、6分钟步行试验和生活质量,并按新冠期间是否发生肺炎分组。中位135天后68.6%的患者仍报告至少一种症状;曾发生肺炎者静息和步行时SpO2、肺总量等指标更差。新冠期间SpO2/FIO2比值和PSI与中期肺功能损害直接相关。
要点
- 新冠后4个月多数患者仍有症状,需关注中期随访。
- 新冠期间发生肺炎者中期肺功能和运动能力损害更明显。
- 急性期SpO2/FIO2比值和PSI可提示中期肺功能损害风险。
核心结论
- COVID-19期间的肺损伤与急性感染后4个月肺功能下降相关。
研究设计与样本
- 研究纳入379例SARS-CoV-2确诊患者,在诊断后4个月进行评估,按新冠期间是否发生肺炎分为两组。
- 评估内容包括临床状况、生活质量、症状、6分钟步行试验、肺功能(含肺量计和DLCO),并与急性期临床演变比较。
主要发现
- 中位135天后,379例中260例(68.6%)报告至少一种症状。
- 新冠期间发生肺炎者较无肺炎者静息SpO2(p<0.001)、6分钟步行试验中SpO2(p<0.001)、肺总量(p<0.001)、P0.1(p=0.02)、P0.1/MIP比值(p=0.005)更低。
- 新冠期间发生肺炎者Borg评分(p=0.006)和mMRC呼吸困难量表(p=0.003)更高。
- 新冠期间SpO2/FIO2比值和PSI与中期静息SpO2(p<0.001)、6分钟步行试验中SpO2(p<0.001)、残气量(p<0.001)、肺总量(p<0.001和p=0.003)及FVC(p=0.004和p=0.03)的异常直接相关。
临床怎么用
- 对新冠期间发生肺炎、SpO2/FIO2比值低或PSI高的患者,应在感染后数月关注肺功能、运动能力和呼吸困难评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide, having a dramatic impact on healthcare systems. The aim of this study is to evaluate mid-term clinical impact of COVID-19 on respiratory function. METHODS: 379 patients were evaluated 4 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis. Patients were divided in two groups based on the presence of pneumonia during COVID-19. Clinical conditions, quality of life, symptomatology, 6-min walk test, pulmonary function test with spirometry and diffusing capacity of the lung for carbon monoxide were analysed. Data were compared to clinical evolution during COVID-19 (development of acute respiratory distress syndrome, need of invasive mechanical ventilation, partial oxygen saturation (S pO2 )/inspiratory oxygen fraction (F IO2 ) ratio and pneumonia severity index (PSI)). RESULTS: After a median 135 days, 260 (68.6%) out of 379 patients referred at least one symptom. Patients who developed pneumonia during COVID-19 showed lower S pO2 at rest (p<0.001), S pO2 during 6-min walk test (p<0.001), total lung capacity (p<0.001), airway occlusion pressure after 0.1 s (P 0.1) (p=0.02), P 0.1/maximal inspiratory pressure ratio (p=0.005) and higher Borg category-ratio scale (p=0.006) and modified Medical Research Council breathlessness scale (p=0.003), compared to patients without pneumonia. S pO2 /F IO2 ratio and PSI during SARS-CoV-2 pneumonia were directly associated with mid-term alteration of S pO2 at rest (p<0.001) and during 6-min walk test (p<0.001), residual volume (p<0.001), total lung capacity (p<0.001 and p=0.003, respectively) and forced vital capacity (p=0.004 and p=0.03, respectively). CONCLUSION: Lung damage during COVID-19 correlates to the reduction of pulmonary function 4 months after acute infection.
引用
- Anastasio F, Barbuto S, Scarnecchia E, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021. PMID: 33574080. doi:10.1183/13993003.04015-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。